Today, Zealand Pharma A/S, a biotechnology company transforming lives with cutting-edge peptide-based medicines, and Iktos, a company specializing in artificial intelligence for new drug design, announced a research collaboration to co-develop generative and predictive AI technologies for peptide drug design.
With its deep data-driven chemical structure creation technology, Iktos’ AI technology revolutionizes the drug discovery process. With the help of this technology, virtual new molecules with all the qualities of a potent medication molecule are automatically designed. In order to assist the design of innovative peptide treatments with desired qualities, Iktos has lately broadened its research and development activities into the development of an AI technology for peptide-based medicines. To this end, the company has created cutting-edge generative and predictive models.
Zealand Pharma A/S has demonstrated success in the invention and development of innovative peptide-based pharmaceuticals. This accomplishment is a result of years of experience in enhancing peptides’ medicinal properties. Zealand Pharma (https://www.zealandpharma.com/) is very interested in adding AI and machine learning based methods to its repertoire of computational chemistry tools for the creation of new therapeutic peptides.
As per the agreement, Iktos’ generative modeling technologies and machine learning and artificial intelligence skills will benefit from Zealand’s peptide drug discovery experience.
Yann Gaston-Mathé, President and CEO of Iktos, stated, “We are very pleased to join forces with Zealand Pharma and leverage their deep know-how in peptide therapeutics with our state-of-the-art existing technology assets to peptide drug discovery.” “We are excited to collaborate with Zealand’s skilled research and development team to develop cutting-edge peptide generative and predictive modeling technology, which will open up new opportunities for Iktos.”
